The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Middle District of Tennessee on behalf of shareholders of Revance Therapeutics, Inc. who purchased Securities between February 29, 2024 and December 6, 2024.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance “the exclusive right to import, market, promote, sell and distribute Teoxane’s line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until March 4, 2025 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
